Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9

Oncotarget
I-Chih ChenTing-Hsing Chao

Abstract

The protein complex proprotein convertase subtilisin/kexin type 9 (PCSK9) serves as an important target for the prevention and treatment of atherosclerosis and lipid homeostasis. This study investigated the effect of cilostazol on plasma PCSK9 concentrations. We performed a post hoc analysis of two prospective, double-blind, randomized controlled trials including 115 patients of whom 61 received cilostazol 200 mg/day and 54 received placebo for 12 weeks. Linear regression analysis was performed to determine the associations between several parameters and changes in PCSK9 levels. Use of cilostazol, but not placebo, significantly increased plasma PCSK9 concentrations, high-density lipoprotein cholesterol levels, and number of circulating endothelial progenitor cells (EPCs), and decreased triglyceride levels with a trend toward an increase in total cholesterol (TC) levels. A reduction in hemoglobin A1C and an increase in plasma vascular endothelial growth factor and adiponectin levels with cilostazol treatment were also found. Changes in the number of circulating EPCs were positively correlated and the TC concentrations were inversely correlated with changes in the PCSK9 levels. After adjusting for changes in levels of TC and numb...Continue Reading

References

Sep 9, 2005·The New England Journal of Medicine·Anthony Rosenzweig
Mar 24, 2006·The New England Journal of Medicine·Jonathan C CohenHelen H Hobbs
Jul 22, 2008·Biochemical and Biophysical Research Communications·Kenneth R FeingoldCarl Grunfeld
Feb 17, 2009·Journal of Vascular Surgery·Mark E O'DonnellChee V Soong
Apr 5, 2012·International Journal of Cardiology·Federico BiscettiAndrea Flex
Aug 27, 2013·Journal of the American College of Cardiology·Daniel UrbanUlrich Laufs
Nov 21, 2013·Biomarker Research·Seungbum Choi, Ron Korstanje
Nov 21, 2014·Journal of Atherosclerosis and Thrombosis·Sha Li, Jian-Jun Li
Feb 24, 2015·Molecular and Cellular Endocrinology·Arif U HasanMasakazu Kohno
Jun 21, 2015·Cardiovascular Research·Zufeng DingJawahar L Mehta
Jul 15, 2015·Arteriosclerosis, Thrombosis, and Vascular Biology·Mikaël CroyalEstelle Nobécourt
Aug 22, 2015·Arteriosclerosis, Thrombosis, and Vascular Biology·Yiming M ZhuSubodh Verma
Sep 1, 2015·Journal of Biomedical Research·I DruceT C Ooi

❮ Previous
Next ❯

Citations

Jul 1, 2021·The Cochrane Database of Systematic Reviews·Tamara BrownMarlene Stewart

❮ Previous
Next ❯

Methods Mentioned

BETA
density gradient centrifugation

Clinical Trials Mentioned

NCT01952756
NCT02194686

Software Mentioned

SPSS

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.